DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab and tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative HNSCC—Results of the preplanned feasibility interim analysis.

Konrad Friedrich Klinghammer,Thomas Christoph Gauler,Carmen Stromberger, Grzegorz Kofla,Maike de Wit,Johannes Gollrad, Izabella Rauer,Peter Martus,Inge Tinhofer,Volker Budach,Ulrich Keilholz,Susen Burock

Journal of Clinical Oncology（2020）

引用 4|浏览1

暂无评分

摘要

6574Background: DURTRERAD is a randomized phase II study evaluating feasibility and efficacy of durvalumab (anti-PD-L1) vs. durvalumab and tremelimumab (anti-CTLA-4) in combination with radiotherap...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要